Please ensure Javascript is enabled for purposes of website accessibility

Poll: Katie Porter Holds Early Edge in California Governor’s Race

1 hour ago

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

2 hours ago

Families Leave Gaza City After Night of Bombardment, Israelis Protest

4 hours ago

California Farming Couple Seeks $300 Million for Aspen Estate

5 hours ago

Trump Administration Cannot Sue Maryland Federal Judges Over Immigration Order, Judge Rules

6 hours ago

California Republicans Sue to Block Congressional Redistricting Plan

21 hours ago

Trump To Sign Executive Order Directing AG To Prosecute Flag Desecration

1 day ago

Fresno County DUI Crash Sends Car Into Embankment Near Highway 99

1 day ago
Panel Endorses Widespread Use of Pfizer COVID-19 Vaccine in US
gvw_ap_news
By Associated Press
Published 5 years ago on
December 10, 2020

Share

A government advisory panel endorsed widespread use of Pfizer’s coronavirus vaccine Thursday, putting the country just one step away from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

Shots could begin within days, depending on how quickly the Food and Drug Administration signs off, as expected, on the expert committee’s recommendation.

In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and older.

That endorsement came despite questions about allergic reactions in two people who received the vaccine earlier this week when Britain became the first country to begin dispensing the Pfizer-BioNTech shot.

Despite all the remaining unknowns, in an emergency, “the question is whether you know enough,” said panel member Dr. Paul Offit of Children’s Hospital of Philadelphia, who concluded that the shot’s potential potential benefits outweigh its risks.

The independent review by non-government experts in vaccine development, infectious diseases and medical statistics was considered critical to boosting Americans’ confidence in the safety of the shot, which was developed at breakneck speed less than a year after the virus was identified.

The decision came as COVID-19 cases surge to ever-higher levels across the U.S., with deaths hitting an all-time, one-day high of more than 3,100 on Wednesday.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. But initial supplies will be limited and reserved primarily for health care workers and nursing home residents, with other vulnerable groups next in line until the shots become widely available on demand, something that will probably not happen until the spring.

The FDA Next Week Will Review a Second Vaccine

Experts estimate at least 70% of the U.S. population will have to be vaccinated to achieve herd immunity, the point at which the virus can be held in check. That means it could be several months before things start get back to normal and Americans can put away their masks.

The FDA next week will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. A third candidate, from Johnson & Johnson, which would require just one dose, is working its way through the pipeline. Behind that is a candidate from AstraZeneca and Oxford University

All eyes now turn to the FDA staff scientists who will make the final decision on whether to greenlight use of the Pfizer-BioNTech vaccine. Regulators not only in Britain but in Canada have already approved it for use in their countries, and President Donald Trump and White House officials have complained for weeks about the pace of FDA’s careful review.

FDA’s vaccine director Dr. Peter Marks said ahead of the expert meeting that a decision would come within “days to a week.”

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision,” FDA Commissioner Stephen Hahn said before the meeting.

A positive vote for the vaccine was virtually assured after FDA scientists issued a glowing review of the vaccine earlier in the week. Agency staffers said data from Pfizer’s ongoing study of 44,000 people showed strong protection across different age groups, races and health conditions with no major, unexpected safety problems.

It Is Not Yet Clear if It Can Stop the Silent, Symptomless Spread

The Pfizer-BioNTech shot remains experimental because that final-stage study isn’t complete. As a result, the expert panel wrestled with a list of questions that have yet to be answered.

For example, while the vaccine is more than 90% effective in blocking the symptoms of COVID-19, the FDA’s advisers stressed it is not yet clear if it can stop the silent, symptomless spread that accounts for up to half of cases.

“Even though the individual efficacy of this vaccine is very, very, very high, you really as of right now do not have any evidence” that it will lower transmission, said Dr. Patrick Moore of the University of Pittsburgh. He urged Pfizer to take additional steps to answer that question.

And the advisers are worried that Pfizer will lose its opportunity to answer critical questions as it begins offering the real vaccine to study participants who had been getting dummy shots.

The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.

Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

On the safety front, as widespread vaccinations begin, the first recipients will be closely tracked by government health authorities since studies in tens of thousands of people can’t detect rare risks that strike 1 in a million. Hanging over the meeting were the British allergic reactions and a warning from authorities there that people with a history of serious reactions shouldn’t get the vaccine for now.

Pfizer representatives said they have seen no signs of allergic reactions in their trial. But some of the FDA advisers fear the British warning will deter millions of Americans with allergies who might benefit from the COVID-19 vaccine from giving it a try, and urged additional studies to try to settle the issue.

“This issue is not going to die until we have better data,” Offit said.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

California High-Speed Rail Project Hit With New $175 Million Cut

DON'T MISS

Poll: Katie Porter Holds Early Edge in California Governor’s Race

DON'T MISS

Fresno Restaurateur Bobby Salazar Charged by Feds With Arson

DON'T MISS

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

DON'T MISS

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

DON'T MISS

ICE Is Suddenly Showing Up in CA Hospitals. Workers Want More Guidance on What to Do

DON'T MISS

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

DON'T MISS

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

DON'T MISS

Taylor Swift, Travis Kelce Announce Engagement

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Enrique Arellano Ochoa

UP NEXT

Poll: Katie Porter Holds Early Edge in California Governor’s Race

UP NEXT

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

UP NEXT

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

UP NEXT

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

UP NEXT

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

UP NEXT

Trump Urges Cracker Barrel to Revert to Old Logo

UP NEXT

California Farming Couple Seeks $300 Million for Aspen Estate

UP NEXT

Trump Administration Cannot Sue Maryland Federal Judges Over Immigration Order, Judge Rules

UP NEXT

US Threatens to Withhold Funding From States Over Truck Driver English Proficiency Rules

UP NEXT

Trump Takes His Fed Fight to Unprecedented Level With Effort to Fire Cook

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

2 hours ago

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

2 hours ago

ICE Is Suddenly Showing Up in CA Hospitals. Workers Want More Guidance on What to Do

3 hours ago

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

3 hours ago

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

3 hours ago

Taylor Swift, Travis Kelce Announce Engagement

3 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Enrique Arellano Ochoa

3 hours ago

Wilted Lettuce. Rotten Strawberries. Here’s What Happens When You Round Up Farmworkers.

4 hours ago

Big Tower District Name to Reopen Sequoia Brewing Co. in Fresno

4 hours ago

Families Leave Gaza City After Night of Bombardment, Israelis Protest

4 hours ago

California High-Speed Rail Project Hit With New $175 Million Cut

The U.S. Transportation Department said on Tuesday it is cancelling $175 million for four projects that are part of California’s high-...

11 minutes ago

A drone view of a California High-Speed Rail Bridge as it crosses over the Fresno River in Madera, California, U.S. June 7, 2025. (Reuters File)
11 minutes ago

California High-Speed Rail Project Hit With New $175 Million Cut

Katie Porter speaking at the CADEM Endorsing Convention General Session Senate Candidate Interviews Saturday afternoon.
1 hour ago

Poll: Katie Porter Holds Early Edge in California Governor’s Race

bobby salazar
2 hours ago

Fresno Restaurateur Bobby Salazar Charged by Feds With Arson

Members of the National Guard walk at the National Mall after U.S. President Donald Trump deployed National Guard troops and ordered an increased presence of federal law enforcement to assist in crime prevention, in Washington, D.C., U.S., August 21, 2025. (Reuters File)
2 hours ago

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

President Donald Trump holds a cabinet meeting at the White House in Washington, D.C., U.S., August 26, 2025. (Reuters File)
2 hours ago

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

A view of a sign for the Dignity Health Glendale Memorial Hospital.
3 hours ago

ICE Is Suddenly Showing Up in CA Hospitals. Workers Want More Guidance on What to Do

A student at Coarsegold Elementary accidentally brought an unloaded starter pistol to school Monday, August 26, 2025, prompting a brief lockdown that has since been lifted, authorities said. (Madera County SO)
3 hours ago

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

A person walks outside of the U.S. Department of Health and Human Services building after it was reported that the HHS will cut about 10,000 full-time jobs and close half of its regional offices, a major overhaul of the department under Health Secretary Robert F. Kennedy Jr., in Washington, D.C., U.S., March 27, 2025. (Reuters File)
3 hours ago

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

Search

Help continue the work that gets you the news that matters most.

Send this to a friend